In his article, "Genetic Testing for Cancer Susceptibility: Challenges for Creators of Practice Guide-lines" [11(11A):171-176, 1997], Henry Greely, JD, provides a comprehensive review of the complex issues that patients consider when deciding
Catherine Walsh Vockely, MS
Advertisement
Articles by Catherine Walsh Vockely, MS
Advertisement
Latest Updated Articles
- Expertise of Genetic Counselors Clarified
July 1st 1998
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Permits Expanded Daraxonrasib Access in Previously Treated Metastatic PDAC
2
FDA Approves Vepdegestrant in ER+, HER2–, ESR1-Mutated Breast Cancer
3
FDA ODAC Votes No to Camizestrant for HR+/HER2– ESR1 Advanced Breast Cancer
4
TIP137 ADELA: A Double-blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus Versus Elacestrant + Placebo in ER+/HER2- Advanced Breast Cancer (aBC) Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy (ET) + CDK4/6i
5